ViaCyte to Present at ARM's 5th Annual Cell & Gene Therapy Investor Day in Boston

SAN DIEGO, April 24, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced two presentations on April 27 at the Alliance for Regenerative Medicine's 5th Annual Cell & Gene Therapy Investor Day in Boston.  ViaCyte is developing novel stem cell-derived islet replacement therapies for insulin-requiring diabetes.  The company's lead PEC-Direct™ product candidate is entering clinical development as a potential functional cure for patients with type 1 diabetes with the highest risk of life threatening acute complications.  The related PEC-Encap™ product candidate in development has the potential to provide a functional cure for essentially all patients with type 1 diabetes as well as become an important therapy for patients with type 2 diabetes that depend on insulin to help control their disease.  

A live webcast at the 5th Annual Cell & Gene Therapy Investor Day will be available at the time of the presentations here: http://www.arminvestorday.com/webcast.

ViaCyte will also present at the upcoming World Advanced Therapies and Regenerative Medicine Congress in London on May 19.

Details of the presentations are as follows:

For more information about ViaCyte's participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/

About ViaCyte

ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to reduce the risk of hypoglycemia and diabetes-related complications.  ViaCyte's product candidates are based on the derivation of pancreatic progenitor cells, which are then implanted in durable and retrievable cell delivery devices.  Once implanted and matured, these cells are designed to secrete insulin and other pancreatic hormones in response to blood glucose levels.  ViaCyte has two products in development.  The PEC-Direct™ product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device that allows direct vascularization of the implant in order to insure a robust and consistent engraftment and is being developed for type 1 diabetes patients who have severe hypoglycemic episodes, extreme glycemic lability, and/or impaired awareness of hypoglycemia.  The PEC-Encap™ (also known as VC-01) product candidate is designed to deliver the same pancreatic progenitor cells in an immunoprotective device and is currently in active development as a therapy for all patients with type 1 diabetes as well as insulin requiring patients with type 2 disease.  ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.  For more information on ViaCyte, please visit www.viacyte.com and connect with ViaCyte on Twitter and Facebook.

SOURCE ViaCyte, Inc.

Related Links

http://www.viacyte.com